Literatur
Van Cutsem E, Peeters M, Siena S et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658–1664
Amado RG et al. Eur J Cancer 5(4–6) 7 LB, Abstract 0007
De Roock W, Piessevaux H, De Schutter J (2007) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol (Epub ahead of print)
Freeman et al. Eur J Cancer 5(4–6) 7 LB, Abstract 3014
Tabernero J (2007) The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5: 203–220
Interessenkonflikt
Keine Angaben.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tannapfel, A. Molekularpathologische Analyse des KRAS-Mutationsstatus beim metastasierten kolorektalen Karzinom. Pathologe 29, 93–96 (2008). https://doi.org/10.1007/s00292-007-0966-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00292-007-0966-y